reports
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy ...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO. This press release features multimedia. View the full release here: Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business ...
STAAR Surgical to Report First Quarter Results on May 7, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close. STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for d...
Edwards Lifesciences to Host Earnings Conference Call on April 25, 202...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart d...
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company obtained U.S. FDA approval of the EVO ICL in March 2022. The Company is providing this informatio...
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meetin...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters...
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1 This press release features multimedia. View the full release here: (Graphic: STAAR Surgical) “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens mile...
- Jonathan Moreland
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. “Art Butcher and Wei Jiang are seasoned executives with broad leadershi...
STAAR Surgical to Participate in Two Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti Small Cap Conference, Wednesday, March 13 Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20. Investor pa...
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year ended December 29, 2023. Fourth Quarter 2023 Overview Net sales up 19% to $76.3 million in the fourth quarter ICL sales up 22% to $74.6 million and ICL units up 19% Gross margin at 79.6% vs. 77.7% year ago Net income of $7.8 million vs. $6.8 million year ago Earnings per share of $0.1...
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural he...
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 877...
Edwards Lifesciences Reports Fourth Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying moderate AS patients Received early FDA approval for EVOQUE; ongoing European l...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
CODI COMPASS DIVERSIFIED HOLDINGS
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
RLMD RELMADA THERAPEUTICS
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CLF CLIFFS NATURAL RESOURCES INC.
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
RCUS ARCUS BIOSCIENCES
AKTS AKOUSTIS TECHNOLOGIES INC
TLRY TILRAY
PAYS PAYSIGN INC
FBIO FABIEN CORP
ACET ADICET BIO INC
GRPN GROUPON INC.
VRDN VIRIDIAN THERAPEUTICS INC
AGL AGILON HEALTH
TBBK INC.
MPA THE BANCORP
SLDB INC.
COLB BLACKROCK MUNIYIELD PENNSYLVANIA FD
CRBP SOLID BIOSCIENCES INC
LSXMK COLUMBIA BANKING SYSTEM
INC.
CORBUS PHARMACEUTICALS HOLDINGS INC.
LIBERTY SIRIUSXM GROUP
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural hea...
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
FDX FEDEX CORPORATION
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
FIZZ NATIONAL BEVERAGE CORP.
FBK FB FINANCIAL CORPORATION
PKTX PROTOKINETIX INC
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
ACET FABIEN CORP
GRPN ADICET BIO INC
HPK GROUPON INC.
ATHA HIGHPEAK ENERGY INC (A)
VRDN ATHIRA PHARMA
AGL VIRIDIAN THERAPEUTICS INC
MPA AGILON HEALTH
SLDB INC.
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and Austin, today announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses. This press release features multimedia. View the full release here: Dr. Matthew Sharpe, SharpeVision (Photo: Business Wire) STAAR...
- Rachel Birkett
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
LPSN LIVEPERSON INC.
FLO FLOWERS FOODS INC.
FDX FEDEX CORPORATION
DLTR DOLLAR TREE INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
CYAN CYANOTECH
FIZZ NATIONAL BEVERAGE CORP.
PKTX PROTOKINETIX INC
CMXC CELL MEDX
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
HPK FABIEN CORP
ATHA HIGHPEAK ENERGY INC (A)
HQI ATHIRA PHARMA
AGL HIREQUEST INC.
TCRX AGILON HEALTH
BCAB INC.
MPA FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
SLDB BIOATLA INC
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.